Free tool
FAERS Monitor: Myqorzo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219083 or its brand name (Myqorzo, Aficamten). Reports on generic versions are filed under their own applications.
Reports
497
Serious
159
32% of reports
Hospitalization
99
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea58
- fatigue45
- dizziness44
- product dose omission issue44
- blood pressure increased33
- chest pain33
- headache26
- product use issue22
- atrial fibrillation17
- peripheral swelling17
- drug ineffective16
- asthenia15
- palpitations15
- cardiac failure14
- malaise14
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 497 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,662 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood pressure increasedSignal | 33 | 9.1 | 6.6 | 233 |
| chest painSignal | 33 | 7.5 | 5.4 | 182 |
| atrial fibrillationSignal | 17 | 7.4 | 4.6 | 88 |
| cardiac failureSignal | 14 | 7.4 | 4.4 | 71 |
| product dose omission issueSignal | 44 | 6.3 | 4.8 | 195 |
| palpitationsSignal | 15 | 5.4 | 3.3 | 50 |
| product use issueSignal | 22 | 5.0 | 3.3 | 66 |
| peripheral swellingSignal | 17 | 4.7 | 2.9 | 46 |
| dyspnoeaSignal | 58 | 4.3 | 3.4 | 150 |
| dizzinessSignal | 44 | 3.7 | 2.8 | 87 |
| fatigueSignal | 45 | 2.4 | 1.9 | 38 |
| headache | 26 | 1.8 | 1.2 | 8 |
| asthenia | 15 | 1.7 | 1.0 | 4 |
| malaise | 14 | 1.4 | 0.8 | 1 |
| drug ineffective | 16 | 0.5 | 0.3 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.